Onconova Therapeutics (NASDAQ: ONTX) Decreased to Hold at Zacks Investment Research

ONTX was devalued by Zacks.com  from a “buy” ranking to a “hold” rating in a research note provided to investors on Thursday, Zacks.com records.

According to Zacks, “Onconova Therapeutics, Inc. runs as a clinical-stage biopharmaceutical company. It concentrates on discovering and also developing small particle drug prospects to deal with cancer. The Firm’s products under different stages of growth include Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 as well as Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Several various other equities research analysts likewise lately discussed the company. Noble Financial reissued a “get” score and provided a $11.00 cost goal on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and also set a “get” ranking on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 and also a twelve month high of $28.95. The business has a 50 day relocating ordinary price of $2.90 and also a two-hundred day relocating average rate of $4.16. The business has a market cap of $46.76 million, a P/E proportion of -1.82 and a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last released its quarterly profits outcomes on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) profits per share for the quarter, covering analysts’ consensus estimates of ($ 0.33) by $0.11. Onconova Therapeutics had an unfavorable return on equity of 59.78% and an unfavorable internet margin of 8,294.27%. The company had profits of $0.06 million throughout the quarter, compared to the agreement estimate of $0.06 million. Throughout the same quarter in the previous year, the firm posted ($ 0.45) EPS. En masse, research analysts anticipate that Onconova Therapeutics will post -1.18 EPS for the current year.

A number of hedge funds have lately dealt shares of ONTX. GSA Funding Allies LLP purchased a new position in Onconova Therapeutics during the third quarter worth $922,000. Hudson Bay Funding Management LP acquired a brand-new setting in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC bought a new placement in shares of Onconova Therapeutics in the 3rd quarter worth $575,000. CVI Holdings LLC purchased a brand-new position in shares of Onconova Therapeutics in the 3rd quarter worth $493,000. Ultimately, Dimensional Fund Advisors LP bought a brand-new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and other institutional financiers have 13.36% of the business’s stock.

Concerning Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical company, which engages in the identification as well as development of oncology therapeutics. It focuses on uncovering as well as developing tiny particle drug candidates to deal with cancer. The firm was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Obtain a totally free copy of the Zacks research record on Onconova Therapeutics (ONTX).

For more information concerning research offerings from Zacks Investment Research, see Zacks.com.

This immediate information alert was generated by narrative scientific research modern technology and financial information from Market in order to offer visitors with the fastest as well as most exact coverage. This story was examined by Market’s content group prior to magazine. 



Before you consider Onconova Therapeutics, you’ll want to hear this.

Market keeps an eye on Wall Street’s top-rated and ideal performing research experts and also the stocks they recommend to their customers on a daily basis. Market has recognized the 5 stocks that top experts are quietly whispering to their customers to purchase now before the wider market catches on … and also Onconova Therapeutics wasn’t on the checklist.

While Onconova Therapeutics currently has a “Buy” ranking among experts, premier experts think these 5 stocks are better purchases.

Related Post